MasterGraft™ Resorbable Ceramic is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. MasterGraff™ Resorbable Ceramic is to be gently packed into bony voids of the skeletal system (e.g., the spine, pelvis, ilium, and/or extremities). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. MasterGraft™ provides a bone void filler that resorbs and is replaced with bone during the healing process.

Device Description

MasterGraft™ Resorbable Ceramic is made of medical grade combination of hydroxyapatite and ß-tricalcium phosphate. MasterGraft™ is provided in a 60 percent hydroxyapatite and 40 percent ß-tricalcium phosphate formulation. Alternatively, MasterGraft™ may be provided in a 15 percent hydroxyapatite and 85 percent ß-tricalcium phosphate formulation. The product is supplied sterile for single patient use. MasterGraft™ is an osteoconductive porous implant.

AI/ML Overview

This document is a 510(k) summary for the Medtronic Sofamor Danek MasterGraft™ Resorbable Ceramic. A 510(k) submission is a premarket notification demonstrating that a device is at least as safe and effective as a legally marketed predicate device. This type of submission generally does not include detailed studies on performance against specific acceptance criteria in the way a clinical trial for a new drug or a novel, high-risk device might.

Based on the provided text, the submission focuses on demonstrating substantial equivalence to existing predicate devices, rather than establishing specific performance metrics against pre-defined acceptance criteria through a standalone study. Therefore, most of the requested information (acceptance criteria table, sample sizes, expert qualifications, adjudication, MRMC, standalone performance, ground truth details, training set size) is not present in this type of document.

Here's a breakdown of what can be extracted and what is missing:

1. A table of acceptance criteria and the reported device performance

Missing. This document does not describe specific numerical acceptance criteria (e.g., a certain percentage of bone regeneration, or a specific mechanical strength) or report performance against such criteria. The entire premise of a 510(k) is to demonstrate substantial equivalence, not to prove novel performance metrics.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Missing. No test set or associated sample size is mentioned. The submission is based on demonstrating equivalence, likely through material characterization, predicate device literature review, and potentially some in-vitro or animal testing (though not detailed here).

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

Missing. Not applicable for a substantial equivalence submission of this nature. There is no mention of a test set requiring expert-established ground truth.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Missing. Not applicable.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Missing. Not applicable. This device is a bone void filler, not an AI-assisted diagnostic tool.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Missing. Not applicable. This device is a bone void filler, not an algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Missing. While the device is intended to be replaced by bone during healing, the 510(k) summary does not describe specific studies that established "ground truth" using pathology or outcomes data in the context of a clinical performance study. The ground truth for substantiating equivalence would be data supporting the properties and efficacy of the predicate devices.

8. The sample size for the training set

Missing. Not applicable. This is not an AI/machine learning device.

9. How the ground truth for the training set was established

Missing. Not applicable.

Summary of the Study that Proves the Device Meets Acceptance Criteria (as interpreted for a 510(k)):

The "study" described in this document is a demonstration of Substantial Equivalence to legally marketed predicate devices, not a study proving the device meets specific (new) performance acceptance criteria.

Substantial Equivalence Claim: The documentation "demonstrated the MasterGraft™ Resorbable Ceramic to be substantially equivalent to itself and Interpore Cross International ProOsteon 500R (K990131)."
Purpose of Submission: The specific purpose of this particular submission was to:
- Increase the granule size of the MasterGraft™ device.
- Expand the indications to include the ilium.
Implied Acceptance Criteria (for substantial equivalence): The implied acceptance criteria are that the modifications (larger granule size, expanded indication to ilium) do not alter the fundamental safety and effectiveness profile of the device such that it is no longer substantially equivalent to its own previous version or the identified predicate device ProOsteon 500R, for its stated indications. This would typically involve demonstrating similar material properties, biocompatibility, and intended function. The FDA's letter confirms that the review found the device to be substantially equivalent for the stated indications for use.

In conclusion, this regulatory document does not contain the level of detail requested concerning specific acceptance criteria and detailed study methodology because it is a 510(k) submission focused on demonstrating substantial equivalence rather than a detailed performance study against novel, quantitative acceptance criteria.

Summary

{0}------------------------------------------------

JUL 2 2 2002

page 1 of 1

Medtronic Sofamor Danek MasterGraft™ Resorbable Ceramic 510(K) Summary - K020986 May 2002

Medtronic Sofamor Danek USA I. Company: 1800 Pvramid Place Memphis. TN 38132 (901) 396-3133

Proposed Proprietary Trade Name: MasterGraft™ Resorbable Ceramic II.

III. Product Description

IV. Indications

MasterGraft™ Resorbable Ceramic is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. MasterGraft™ Resorbable Ceramic is to be gently packed into bony voids of the skeletal system (e.g., the spine, pelvis, ilium, and/or extremities). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. MasterGraft™ provides a bone void filler that resorbs and is replaced with bone during the healing process.

V. Purpose of the Submission

The purpose of this submission was to increase the granule size of the MasterGraft™ device and to expand the indications to include the ilium.

VI. Substantial Equivalence

Documentation was provided which demonstrated the MasterGraft™ Resorbable Ceramic to be substantially equivalent to itself and Interpore Cross International ProOsteon 500R (K990131).

{1}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/1/Picture/1 description: The image contains the text "Public Health Service". The text is in a simple, sans-serif font and is horizontally aligned. The words are stacked on a single line.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 2 2 2002

Richard W. Treharne, Ph.D. Senior Vice President Regulatory Affairs Medtronic Sofamor Danek 1800 Pyramid Place Memphis, Tennessee 38132

Re: K020986

Trade/Device Name: MasterGraft™ Resorbable Ceramic Regulatory Class: Unclassified Product Code: MQV Dated: May 3, 2002 Received: May 7, 2002

Dear Dr. Treharne:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{2}------------------------------------------------

Page 2 - Richard W. Treharne, Ph.D.,

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Mark A. Melberon

Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

510(k) Number (if known): K020986

Device Name:__________________________________________________________________________________________________________________________________________________________________ MasterGraft™ Resorbable Ceramic

Indications for Use:

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109) (Optional 1-2-96)

Over-the-counter Use __

for Mark A. Millman

General, Restorative and Neurological Devices

510(k) Number _

000031

Regulation Number and Section

§ 888.3045 Resorbable calcium salt bone void filler device.

(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.